Trial Profile
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-756
- Sponsors Merck Sharp & Dohme Corp.
- 09 Dec 2023 Results assessing primary pCR results and residual cancer burden (RCB) outcomes presented at the 46th Annual San Antonio Breast Cancer Symposium.
- 24 Oct 2023 Interim Results (at data cut off May 25, 2023) assessing efficacy of neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembro or pbo + endocrine therapy for early-stage high-risk ER+/HER2 negative breast cancerpresented at the 48th European Society for Medical Oncology Congress
- 20 Oct 2023 According to a Merck media release, data from this trial presented at the European Society for Medical Oncology (ESMO) Congress 2023